 |
 |
This is a reprint of my latest post on NADH - It might be helpful to any new inquiries on NADH. Lisa Carper > >(When all else fails, start typing :) ; sorry for all my confusing posts) >Once again, following is an excerpt from an article on Coenzyme Q10 (ten), NADH and Parkinson's. I realize the article (excerpt) from The Life Extension Magazine is not scientific proof however, the study they are talking about is from Harvard Med School, Mass General Hospital. I spoke with Mass General and they are supposed to fax the actual study soon. For those who may not know, my husband Jeff (PD 6yrs, 45) has taken NADH (4 x 2.5/day) along with a number of vitamins, herbs and so on. Since starting this regemin we have noticed a considerable improvement in his energy level and PD symptons. How much of his improved condition is the NADH, a particular vitamin, herb or any combination will (we) will can't prove, however we are confident in our judgement of Jeff's improved condition. Please make comments freely. >My Very Best Holiday Wishes For All of You, Lisa Carper > >CoQ and Nicotinamide Protect AGainst Neurotoxicity > >MPTP is a neurotoxin that produces clinical, biochemical, and neuropathologic changes in both animals and humans, which are analogous to those found in Parkinson's Disease. Doctors discovered that MPTP could induce Parkinsonism when young people using it as a street drug began to exhibit the symptons of Parkinson's Disease. >Since Parkinson's Disease is characterized by the deterioration of dopamine-producing cells and the excessive degradation of dopamine by the enzyme monoamine oxidase B (MAO-B), the life extension drug deprenyl, which is a selective MAO-B inhibitor and antioxidant can effectively counter the neurotoxic effects of MPTP. >Now there is a new study from the Neurochemistry Laboratory at Harvard Medical School showing that CoQ and/or nicotinamide can counter the effects of mild and moderate MPTP neurotoxicity, and that the combination of both compounds is more effective than either one alone. > >NADH-The High Energy Compound >(an excerpt for article on Coenzyme Q10, The Life Extension Magazine, Feb '96 > >Nicotinamide, in its reduced form NADH, is a high energy compound which is essential for energy production within cells, and which also stimulates the biosynthesis of dopamine, the neurotransmitter which is depleted in Parkinson's Disease. In the June 1995 issue of Life Extension Magazine, we reported that NADH has been used effectively by Dr. Georg Birkmayer of the University of Graz in Vienna to treat patients with Parkinson's Disease, Alzheimers' Disease, and depression. >This new study provides further support for the use of NADH for the treatment of Parkinson's Disease and suggests that the combination of CoQ10 and NADH could be an effective treatment for this disease. It also lends support to the hypothesis that the decline in energy production with advancing age plays a critical role in the genesis and expression of all the diseases of aging. > >ABSTRACT >(This abstract and the actual study are available directly from Mass General Hospital/Harvard Medical School) > >Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. > >Schulz JB; Henshaw DR; Matthews RT; Beal MF >Neurochemistry Laboratory, Massachusetts General Hospital, Boston 02114, USA >Exp Neurol (United States) Apr 1995,132 (2) p279-83 > >1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) produces Parkinsonism in both experimental animals and in man. MPTP is metabolized to 1-methyl-4-phenylpridinium, an inhibitor of mitochondrial comple I. MPTP administration produces ATP depletions in vivo, which may lead to secondary excitotoxicity and free radical generation. If this is the case then agents which improve mitochondrial function or free radical scavengers should attenuate MPTP neurotoxicity. In the present experiments three regimens of MPTP administration produced varying degrees of striatal dopamine depletion. A combination of coenzyme Q10 and nicotinamide protected against both mild and moderate depletion of dopamine. In the MPTP regimen which regemin which produced mild dopamine depletion nicotinamide or the free radical spin trap N-tert-butyl-alpha-(2-sulfonphenyl)-nitrone were also effective. There was no protection with a MPTP regimen which produced severe dopamine depletion. These results show that agents which improve mitochondrial energy production (coenzyme Q10 and nicotinamide NADH) and free radical scavengers can attenuate mild to moderate MPTP neurotoxicity. > --